Caelyx

Overview

Caelyx is a liposomal formulation of doxorubicin, an anthracycline chemotherapeutic agent used in oncology. As a nanomedicine, it is designed to alter the pharmacokinetic and tissue-distribution properties of doxorubicin relative to the free drug, with the goal of improving delivery to tumors while reducing some systemic toxicities. In recent biomedical literature, liposomal doxorubicin is frequently discussed in the context of drug delivery barriers, tumor microenvironment constraints, and combination regimens intended to enhance antitumor activity.

Biologically, Caelyx is relevant because doxorubicin remains a widely used cytotoxic agent across multiple malignancies, including breast, head and neck, colorectal, prostate, and hematologic cancers. Research involving Caelyx often focuses on how liposomal encapsulation interacts with vascular permeability, interstitial fluid pressure, stromal barriers, and adjunctive technologies such as ultrasound, microbubbles, magnetic systems, and radiotherapy to improve intratumoral accumulation. It is also studied in relation to doxorubicin-associated toxicities, especially cardiotoxicity, and to mechanisms of resistance involving apoptosis, redox homeostasis, and the tumor microenvironment.

Focus of Latest Publications

Recent clinical investigations have demonstrated the efficacy of liposomal doxorubicin in combination chemotherapy for advanced solid tumors. A phase II trial evaluated liposomal doxorubicin (20 mg/m²) combined with nab-paclitaxel (120 mg/m²) over three 21-day cycles in patients with unresectable locally advanced or recurrent/metastatic adenoid cystic carcinoma of the head and neck. Among 31 evaluable patients, this regimen achieved an objective response rate of 90.3%, with complete responses in 48.4% and partial responses in 41.9%. Median progression-free survival reached 25.7 months (77.1% at one year), while median overall survival was not reached with 90.0% one-year overall survival. Notably, patients who received concurrent chemoradiotherapy following initial chemotherapy demonstrated substantially prolonged survival outcomes, with median progression-free survival and overall survival not reached compared to 12.8 months and 21.2 months, respectively, in patients treated with chemotherapy alone. The regimen exhibited a manageable safety profile, with grade 3 treatment-related adverse events in 25.8% of patients and no grade 4 events or treatment-related deaths.

Translational research has focused on optimizing liposomal doxorubicin delivery to overcome biological barriers limiting tumor penetration. Recent studies have examined microbubble-mediated focused ultrasound as a strategy to enhance liposomal doxorubicin penetration across the blood–brain barrier and blood–tumor barrier, comparing its efficacy and delivery kinetics against free doxorubicin formulations. These investigations reflect broader efforts to improve the therapeutic window of liposomal doxorubicin through advanced delivery technologies that may expand its applicability to brain tumors and other sanctuary sites.

Key Publications

• NEWJun FAP-α-Responsive Size-Transformable Lipid Nanoparticles for Stromal Remodeling and Enhanced Drug Penetration in Fibrotic Hepatocellular Carcinoma. (ACS applied materials & interfaces, 2026, PMID 42328782): "This developed system, denoted as SOR/DOX@GPA-LNP, is co-loaded with sorafenib and doxorubicin and engineered with three key features: (i) a FAP-α-cleavable GPA peptide linker for TME-specific activation, (ii) FAP-α-mediated targeting of aHSCs, and (iii) a PAMAM core-mediated proton sponge activity to facilitate endosomal escape."
• NEWJul Engineering functionalized carbon dots as biocompatible nanocarriers for controlled doxorubicin delivery in cancer therapy. (Journal of materials chemistry. B, 2026, PMID 42300585): "In this work, we designed and comparatively evaluated β- and γ-cyclodextrin-functionalized carbon dots (β-Cyd-CDs and γ-Cyd-CDs) as nanocarriers for the anthracycline drug doxorubicin (DOX), with the aim of elucidating how cyclodextrin cavity size influences drug-carrier interactions and release behavior."
• NEWJun Liposomal doxorubicin plus nab-paclitaxel with/without chemoradiotherapy in head and neck adenoid cystic carcinoma: single-arm phase II study. (Signal transduction and targeted therapy, 2026, PMID 42285940): "Patients received chemotherapeutic nanomedicines (20 mg/m2 liposomal doxorubicin plus 120 mg/m2 nab-paclitaxel on days 1 and 8) for three 21-day cycles."
• NEWJun Targeted hybrid nanogels for sialic acid-overexpressing lung cancers: DNA-mediated chelation of doxorubicin and adsorption of zinc ions. (International journal of biological macromolecules, 2026, PMID 42276469): "Designed to deliver a pre-mixed DNA-Doxorubicin (DOX) or DNA-Zinc ion (Zn2+) payload, the APBA-crosslinked NGs leverage the acidic tumor microenvironment to ensure precise and controlled therapeutic release."
• Jun Biomedical publication details. (PubMed Database, 2026, PMID 42243048)
• Apr Luminescent Fe3O4 Nanohybrid for Intra-Cellular Imaging and Combinatorial Chemo-Photothermal Therapy in Cancer. (Chembiochem : a European journal of chemical biology, 2026, PMID 42011112): "the presence of hydrophilic surface functional groups in FCDs contributes to the excellent stability in aqueous solutions as well as loading of the anti-cancer drug doxorubicin with a loading capacity of 22 mg g-1."
• May Smart Magnetic Nanozyme for Multimodal Dynamic Regulation to Reverse Multidrug Resistance in Breast Cancer. (Molecular pharmaceutics, 2026, PMID 42007566): "To overcome the redox homeostasis-driven MDR, we analyzed the transcriptomes of 216 breast cancer patients, revealing a noteworthy association between the TRPA1 (a regulator of redox homeostasis) overexpression and drug resistance."
• Apr Phase II Trial of Ixazomib Combined with Gemcitabine and Doxorubicin in Patients with SMARCB1-Deficient Renal Medullary Carcinoma. (Clinical cancer research : an official journal of the American Association for Cancer Research, 2026, PMID 42007903): "testing the proteasome inhibitor ixazomib combined with gemcitabine and doxorubicin."
• Apr Docetaxel-Induced Immune Activation Shows Antitumor Synergy With the Tumor-Targeted CD40 Agonist KK2269. (Cancer science, 2026, PMID 41989931): "KK2269 showed significant antitumor activity in combination with an anti-PD-1 antibody, docetaxel, doxorubicin, or oxaliplatin, but not gemcitabine, with docetaxel showing the most significant antitumor effect(s)."
• Apr Inhalable Cryo-Shocked Tumor Cells for Synergistic Chemoimmunotherapy. (ACS applied materials & interfaces, 2026, PMID 41947504): "...with the preserved cellular architecture of LNT cells enabling the sustained release of doxorubicin (DOX) under physiologically relevant conditions."